The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already struggled to grow sales.

Nine years after selling Medivation to Pfizer for $14 billion, David Hung, M.D., is going toe to toe with the New York ...

The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's drug for patients with a rare and ...

Pfizer Inc. (NYSE: PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug ...

While Pfizer said in its petition for mass tort designation that it expected many of the dismissed plaintiffs to refile their claims, that prediction has not come to fruition. Now, there appears to be ...

Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in ...

A talk with study author on a new combination of acimtamig and an allogeneic natural killer cell product that shows safety and promising objective response rates in patients with few treatment choices ...

OPKO Health strengthens finances by selling BioReference and focusing on drug development. Click here to read an analysis of ...

The Trump administration's cancellation of $766 million in contracts to develop mRNA vaccines against potential pandemic flu ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

Financial disclosure records show that members of the vaccine safety panel fired by HHS Secretary RFK Jr. had financial ties to the pharmaceutical industry.

Four blue-chip stocks are trading near their 52-week lows and offering investors incredible entry points and huge dividends.